Kodiak Sciences Inc. — fact timeline

Kodiak Sciences Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

“The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 was ratified. For Against Abstain Broker Non-Votes 54,716,676 52,962 256,906 —”

Kodiak Sciences Inc. shareholders approved Advisory Approval of the Compensation of Named Executive Officers at the 2026-06-02 meeting.

“The compensation of the Company’s named executive officers was approved, on an advisory basis, by the stockholders. For Against Abstain Broker Non-Votes 49,157,143 323,196 21,005 5,525,200”

Kodiak Sciences Inc. shareholders approved Election of Class II Directors at the 2026-06-02 meeting.

“The following nominees were each elected as a Class II director to serve until the 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified. Nominee For Withheld Broker Non-Votes Charles A. Bancroft 38,940,529 10,560,815 5,525,200 Bassil I. Dahiyat, Ph.D. 48,843,144 658,200 5,525,200 Taiyin Yang, Ph.D. 49,192,610 308,734 5,525,200”

Kodiak Sciences Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $58.2 million, EPS $0.94 per share on a basic and diluted basis.

“Net loss for the first quarter of 2026 was $58.2 million, or $0.94 per share on a basic and diluted basis, as compared to a net loss of $57.5 million, or $1.09 per share on a basic and diluted basis, for the first quarter of 2025.”

Kodiak Sciences Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis.

“On March 31, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2025 and business highlights.”

Kodiak Sciences Inc. reported the quarter ended March 31, 2024 results: net income $43.0 million, or $0.82 per share on both a basic and diluted basis, EPS $0.82 per share on both a basic and diluted basis.

“Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.”

Kodiak Sciences Inc. reported financial results for the quarter and year ended December 31, 2023.

“On March 28, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2023 and business highlights.”

Jason Ehrlich resigned as Chief Medical Officer and Chief Development Officer at Kodiak Sciences Inc..

“On August 16, 2023, Jason Ehrlich, M.D., Ph.D., informed the Company of his resignation as Chief Medical Officer and Chief Development Officer of the Company, effective August 25, 2023.”

Kodiak Sciences Inc. reported the quarter ended June 30, 2023 results: net income $80.2 million, or $1.53 per share on both a basic and diluted basis, EPS $1.53 per share on both a basic and diluted basis.

“The net loss for the second quarter of 2023 was $80.2 million, or $1.53 per share on both a basic and diluted basis”

Kodiak Sciences Inc. reported preliminary financial results for the quarter ended June 30, 2023.

“On July 24, 2023, Kodiak Sciences Inc. (“Kodiak,” or the “Company”) reported that, as of June 30, 2023 (unaudited), the Company had approximately $379 million in cash and cash equivalents.”

Kodiak Sciences Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-06 meeting.

“Proposal Three – Ratification of the Appointment of Independent Registered Public Accounting Firm . The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified. For Against Abstain Broker Non-Votes 41,396,664 29,004 355,235 —”

Kodiak Sciences Inc. shareholders approved Advisory Approval of the Compensation of Named Executive Officers at the 2023-06-06 meeting.

“Proposal Two – Advisory Approval of the Compensation of Named Executive Officers . The compensation of the Company’s named executive officers was approved, on an advisory basis, by the stockholders. For Against Abstain Broker Non-Votes 32,457,916 5,299,673 43,642 3,979,672”

Kodiak Sciences Inc. shareholders approved Election of Class II Directors at the 2023-06-06 meeting.

“Proposal One - Election of Class II Directors. The following nominees were each elected as a Class II director to serve until the 2026 annual meeting of stockholders or until his or her successor is duly elected and qualified. Nominee For Withheld Broker Non-Votes Charles A. Bancroft 29,577,783 8,223,448 3,979,672 Bassil I. Dahiyat, Ph.D. 35,943,055 1,858,176 3,979,672 Taiyin Yang, Ph.D. 35,936,395 1,864,836 3,979,672”

Kodiak Sciences Inc. reported the quarter ended March 31, 2023 results: net income $70.8 million, EPS $1.35 per share.

“The net loss for the first quarter of 2023 was $70.8 million, or $1.35 per share on both a basic and diluted basis”

Kodiak Sciences Inc. reported financial results for the fourth quarter ended December 31, 2022.

“Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022.”

Kodiak Sciences Inc. reported third quarter of 2022 results: net income $77.0 million, or $1.47 per share.

“Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended September 30, 2022.”